Updated:
YuanMing Capital
YuanMing Capital was founded in 2015 as a private equity firm dedicated exclusively to the global healthcare sector.
YuanMing Capital
YuanMing Capital was founded in 2015 as a private equity firm dedicated exclusively to the global healthcare sector. It operates from dual headquarters in New York and Beijing, reflecting a structural commitment to sourcing and scaling biomedical innovation across the US and China. The firm focuses on venture opportunities, targeting early-stage and growth-stage companies in therapeutics, medical devices, and high-end healthcare services. The firm's investment approach mixes direct venture mandates with a fund-of-funds allocation, providing exposure to both company-level risk and diversified GP portfolios. YuanMing targets seed through late-stage venture rounds, with a particular emphasis on cross-border assets that can leverage Chinese manufacturing scale or US clinical-trial infrastructure. Investment cases include Changfeng Pharmaceutical, which YuanMing backed prior to its successful listing on the Hong Kong Stock Exchange in October 2025 (per the firm, October 2025), and Meisheng Group, a high-end medical device company that completed a strategic financing round exceeding CNY 1.5 billion in September 2025 (per the firm, September 2025). The firm maintains offices in New York and Beijing and communicates primarily through its Chinese-language website, signaling an operational center of gravity in cross-border execution rather than purely domestic US activity. YuanMing's professional headcount has not been publicly disclosed. In January 2026, the firm was ranked among the top performers in the Rongzhong 2025 China Equity Investment List (per the firm, January 2026). No separate philanthropic foundations or operating-business arms have been publicly identified. YuanMing's structural differentiator lies in its explicit dual-city architecture: it is neither a Chinese firm with a US outpost nor a US firm exploring China. This design gives it an unusual mandate to underwrite clinical and regulatory risk in two distinct ecosystems simultaneously, an approach that requires fluency in both FDA and NMPA pathways — a genuine governance and operational separation few healthcare funds replicate without relying on third-party advisors.
General information
Firm type
Private Equity
Year founded
2015
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Additional offices
Beijing, China
Sector focus
Frequently asked questions
How does YuanMing Capital structure its cross-border healthcare investments?
YuanMing operates from offices in Beijing and New York, targeting companies that can benefit from China-US regulatory and commercial pathways. The firm typically invests at the venture stage in therapeutics and medical devices, aiming to bridge clinical development across both FDA and NMPA jurisdictions. Its dual-city architecture is designed for direct operational oversight in each market rather than relying solely on local consultants.
What types of healthcare companies does YuanMing Capital back?
The firm invests across drug development, innovative medical devices, and high-end healthcare services. Portfolio examples include Changfeng Pharmaceutical, a respiratory drug company, and Meisheng Group, a precision medical device manufacturer. The website emphasizes backing founders with international vision and professional expertise in the medical field.
Does YuanMing Capital invest exclusively in venture deals?
No, alongside direct venture-stage investments, YuanMing allocates a portion of its capital to fund-of-funds commitments within the healthcare sector. This dual approach allows the firm to access diversified manager risk while maintaining high-conviction direct positions in individual therapeutics and device companies.
Is YuanMing Capital a single family office?
No, YuanMing Capital is structured as a private equity asset manager, not a family office. The source of its capital base is not publicly disclosed, and the firm does not list a founding family or wealth creator on its materials. It operates as an independent investment firm raising third-party capital for its healthcare strategies.
Which regions does YuanMing Capital target?
The firm's mandate is explicitly China-US cross-border, with active deal sourcing in both countries. Its Beijing and New York offices support investment origination and portfolio monitoring across these two primary regulatory and commercial environments. No additional geographic offices have been disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: